Swiss National Bank’s Aegerion Pharmaceuticals AEGR Stock Holding History

Swiss National Bank’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-52,300	Closed	-$188K	–	2623
2016 Q1	$188K	Buy	52,300 +8,400	+19%	+$52K	﹤0.01%	2562
2015 Q4	$443K	Hold	43,900	–	–	﹤0.01%	2326
2015 Q3	$597K	Buy	43,900 +14,500	+49%	+$258K	﹤0.01%	2089
2015 Q2	$558K	Buy	29,400 +1,400	+5%	+$30.3K	﹤0.01%	2179
2015 Q1	$733K	Hold	28,000	–	–	﹤0.01%	1938
2014 Q4	$586K	Hold	28,000	–	–	﹤0.01%	2084
2014 Q3	$935K	Hold	28,000	–	–	﹤0.01%	1707
2014 Q2	$899K	Buy	28,000 +5,000	+22%	+$186K	﹤0.01%	1780
2014 Q1	$1.06M	Buy	23,000 +5,300	+30%	+$311K	﹤0.01%	1673
2013 Q4	$1.26M	Hold	17,700	–	–	﹤0.01%	1360
2013 Q3	$1.52M	Sell	17,700 -600	-3%	-$50.9K	0.01%	1182
2013 Q2	$1.16M	Buy	+18,300	New	+$972K	0.01%	1324

Other funds holding AEGR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Swiss National Bank's AEGR Position: Q2 2016 in Review

Swiss National Bank sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 52,300 shares — an estimated $188K sold.

Swiss National Bank first reported a position in AEGR in Q2 2013 and held it in 12 quarters. The position peaked at $1.52M in Q3 2013. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

Swiss National Bank reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Swiss National Bank sold 52,300 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $188K.
Swiss National Bank first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 12 quarters.
Swiss National Bank's Aegerion Pharmaceuticals position peaked at $1.52M in Q3 2013.
71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on Swiss National Bank's 13F filing for Q2 2016, filed 3 Aug 2016.